Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440268 | 1.00 | GAA (0.44) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL6027856 | 0.91 | GAA (0.50) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL31723914 | 0.85 | GAA (0.43) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL15026749 | 0.85 | GAA (0.45) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL21588244 | 0.84 | GAA (0.55) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL21389843 | 0.84 | BTK (0.53) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL5281585 | 0.83 | GAA (0.58) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL3916388 | 0.83 | GAA (0.58) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL29129524 | 0.83 | GAA (0.58) | GAAKMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL29129581 | 0.83 | GAA (0.58) | GAAKMT2AMEN1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | GAA 106/4885KMT2A 667/4885MEN1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.